Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)
Background Hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in patients with Stage III ovarian cancer following interval cytoreductive surgery (CRS). Optimising patient selection is essential to maximise treatment efficacy and avoid overtreatment. This study aimed to identify biom...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2024-08, Vol.131 (3), p.565-576 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 576 |
|---|---|
| container_issue | 3 |
| container_start_page | 565 |
| container_title | British journal of cancer |
| container_volume | 131 |
| creator | Aronson, S. Lot Walker, Cédric Thijssen, Bram van de Vijver, Koen K. Horlings, Hugo M. Sanders, Joyce Alkemade, Maartje Koole, Simone N. Lopez-Yurda, Marta Lok, Christianne A. R. Rottenberg, Sven van Rheenen, Jacco Sonke, Gabe S. van Driel, Willemien J. Kester, Lennart A. Hahn, Kerstin |
| description | Background
Hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in patients with Stage III ovarian cancer following interval cytoreductive surgery (CRS). Optimising patient selection is essential to maximise treatment efficacy and avoid overtreatment. This study aimed to identify biomarkers that predict HIPEC benefit by analysing gene signatures and cellular composition of tumours from participants in the OVHIPEC-1 trial.
Methods
Whole-transcriptome RNA sequencing data were retrieved from high-grade serous ovarian cancer (HGSOC) samples from 147 patients obtained during interval CRS. We performed differential gene expression analysis and applied deconvolution methods to estimate cell-type proportions in bulk mRNA data, validated by histological assessment. We tested the interaction between treatment and potential predictors on progression-free survival using Cox proportional hazards models.
Results
While differential gene expression analysis did not yield any predictive biomarkers, the cellular composition, as characterised by deconvolution, indicated that the absence of macrophages and the presence of B cells in the tumour microenvironment are potential predictors of HIPEC benefit. The histological assessment confirmed the predictive value of macrophage absence.
Conclusion
Immune cell composition, in particular macrophages absence, may predict response to HIPEC in HGSOC and these hypothesis-generating findings warrant further investigation.
Clinical trial registration
NCT00426257. |
| doi_str_mv | 10.1038/s41416-024-02731-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3067915351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3088987118</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-5b8f956771b6194dc801f257fc866b9ec50ac662fcf7a18023b68554e7064b133</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi1ERbeFF-CALHFpDy52nNjOEa1KW6lSORSuluOdbFxt7GAnlfZZeFmmbAsSBw7WeDTf_B7PT8h7wS8El-ZTqUUtFONVjUdLwdQrshKNrJgwlX5NVpxzzXhb8WNyUsoDpi03-g05lsYo1Sq5Ij_vlzEtmY7B5wTxMeQUR4gz9YPLzs-QQ3FzSJHOiZY5473f0wkDQoX2KdNhP0GeB8ioQUNEBvMwpwhuhzIwpqeim_ZYpEPYDmyb3QZogZyWQtOjy8FF6l30kOnZ3ffrm6-XaybO35Kj3u0KvHuOp-Tbl8v79TW7vbu6WX--ZV5WamZNZ_q2UVqLTom23njDRV81uvf4ya4F33Dnlap632snDK9kp0zT1KC5qjsh5Sk5O-hOOf1YoMx2DMXDbuci4IRWcqVb3GsjEP34D_qA24s4HVLGtEYLYZCqDhTutJQMvZ1yGF3eW8Htk3X2YJ1F6-xv66zCpg_P0ks3wuZPy4tXCMgDULAUt5D_vv0f2V9ccaae</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3088987118</pqid></control><display><type>article</type><title>Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Aronson, S. Lot ; Walker, Cédric ; Thijssen, Bram ; van de Vijver, Koen K. ; Horlings, Hugo M. ; Sanders, Joyce ; Alkemade, Maartje ; Koole, Simone N. ; Lopez-Yurda, Marta ; Lok, Christianne A. R. ; Rottenberg, Sven ; van Rheenen, Jacco ; Sonke, Gabe S. ; van Driel, Willemien J. ; Kester, Lennart A. ; Hahn, Kerstin</creator><creatorcontrib>Aronson, S. Lot ; Walker, Cédric ; Thijssen, Bram ; van de Vijver, Koen K. ; Horlings, Hugo M. ; Sanders, Joyce ; Alkemade, Maartje ; Koole, Simone N. ; Lopez-Yurda, Marta ; Lok, Christianne A. R. ; Rottenberg, Sven ; van Rheenen, Jacco ; Sonke, Gabe S. ; van Driel, Willemien J. ; Kester, Lennart A. ; Hahn, Kerstin ; OVHIPEC-1 Study Group</creatorcontrib><description>Background
Hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in patients with Stage III ovarian cancer following interval cytoreductive surgery (CRS). Optimising patient selection is essential to maximise treatment efficacy and avoid overtreatment. This study aimed to identify biomarkers that predict HIPEC benefit by analysing gene signatures and cellular composition of tumours from participants in the OVHIPEC-1 trial.
Methods
Whole-transcriptome RNA sequencing data were retrieved from high-grade serous ovarian cancer (HGSOC) samples from 147 patients obtained during interval CRS. We performed differential gene expression analysis and applied deconvolution methods to estimate cell-type proportions in bulk mRNA data, validated by histological assessment. We tested the interaction between treatment and potential predictors on progression-free survival using Cox proportional hazards models.
Results
While differential gene expression analysis did not yield any predictive biomarkers, the cellular composition, as characterised by deconvolution, indicated that the absence of macrophages and the presence of B cells in the tumour microenvironment are potential predictors of HIPEC benefit. The histological assessment confirmed the predictive value of macrophage absence.
Conclusion
Immune cell composition, in particular macrophages absence, may predict response to HIPEC in HGSOC and these hypothesis-generating findings warrant further investigation.
Clinical trial registration
NCT00426257.</description><identifier>ISSN: 0007-0920</identifier><identifier>ISSN: 1532-1827</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-024-02731-6</identifier><identifier>PMID: 38866963</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1517/1709 ; 631/67/1857 ; 692/4028/67/1517/1709 ; 692/53/2423 ; Aged ; Biomarkers ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - immunology ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Chemotherapy ; Cystadenocarcinoma, Serous - drug therapy ; Cystadenocarcinoma, Serous - pathology ; Cystadenocarcinoma, Serous - therapy ; Cytoreduction Surgical Procedures ; Drug Resistance ; Epidemiology ; Female ; Gene expression ; Humans ; Hyperthermic Intraperitoneal Chemotherapy ; Lymphocytes B ; Macrophages ; Macrophages - pathology ; Middle Aged ; Molecular Medicine ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Patients ; Transcriptomes ; Tumor Microenvironment ; Tumors</subject><ispartof>British journal of cancer, 2024-08, Vol.131 (3), p.565-576</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Nature Limited.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-5b8f956771b6194dc801f257fc866b9ec50ac662fcf7a18023b68554e7064b133</cites><orcidid>0000-0001-8175-1647 ; 0000-0003-2246-1994 ; 0000-0001-7262-1015 ; 0000-0003-4782-8828 ; 0000-0003-3602-4234 ; 0000-0002-2026-9790 ; 0000-0003-3678-3222 ; 0000-0003-1562-2649 ; 0000-0002-0551-7813</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41416-024-02731-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41416-024-02731-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38866963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aronson, S. Lot</creatorcontrib><creatorcontrib>Walker, Cédric</creatorcontrib><creatorcontrib>Thijssen, Bram</creatorcontrib><creatorcontrib>van de Vijver, Koen K.</creatorcontrib><creatorcontrib>Horlings, Hugo M.</creatorcontrib><creatorcontrib>Sanders, Joyce</creatorcontrib><creatorcontrib>Alkemade, Maartje</creatorcontrib><creatorcontrib>Koole, Simone N.</creatorcontrib><creatorcontrib>Lopez-Yurda, Marta</creatorcontrib><creatorcontrib>Lok, Christianne A. R.</creatorcontrib><creatorcontrib>Rottenberg, Sven</creatorcontrib><creatorcontrib>van Rheenen, Jacco</creatorcontrib><creatorcontrib>Sonke, Gabe S.</creatorcontrib><creatorcontrib>van Driel, Willemien J.</creatorcontrib><creatorcontrib>Kester, Lennart A.</creatorcontrib><creatorcontrib>Hahn, Kerstin</creatorcontrib><creatorcontrib>OVHIPEC-1 Study Group</creatorcontrib><title>Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background
Hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in patients with Stage III ovarian cancer following interval cytoreductive surgery (CRS). Optimising patient selection is essential to maximise treatment efficacy and avoid overtreatment. This study aimed to identify biomarkers that predict HIPEC benefit by analysing gene signatures and cellular composition of tumours from participants in the OVHIPEC-1 trial.
Methods
Whole-transcriptome RNA sequencing data were retrieved from high-grade serous ovarian cancer (HGSOC) samples from 147 patients obtained during interval CRS. We performed differential gene expression analysis and applied deconvolution methods to estimate cell-type proportions in bulk mRNA data, validated by histological assessment. We tested the interaction between treatment and potential predictors on progression-free survival using Cox proportional hazards models.
Results
While differential gene expression analysis did not yield any predictive biomarkers, the cellular composition, as characterised by deconvolution, indicated that the absence of macrophages and the presence of B cells in the tumour microenvironment are potential predictors of HIPEC benefit. The histological assessment confirmed the predictive value of macrophage absence.
Conclusion
Immune cell composition, in particular macrophages absence, may predict response to HIPEC in HGSOC and these hypothesis-generating findings warrant further investigation.
Clinical trial registration
NCT00426257.</description><subject>631/67/1517/1709</subject><subject>631/67/1857</subject><subject>692/4028/67/1517/1709</subject><subject>692/53/2423</subject><subject>Aged</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - immunology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Cystadenocarcinoma, Serous - drug therapy</subject><subject>Cystadenocarcinoma, Serous - pathology</subject><subject>Cystadenocarcinoma, Serous - therapy</subject><subject>Cytoreduction Surgical Procedures</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Hyperthermic Intraperitoneal Chemotherapy</subject><subject>Lymphocytes B</subject><subject>Macrophages</subject><subject>Macrophages - pathology</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Patients</subject><subject>Transcriptomes</subject><subject>Tumor Microenvironment</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi1ERbeFF-CALHFpDy52nNjOEa1KW6lSORSuluOdbFxt7GAnlfZZeFmmbAsSBw7WeDTf_B7PT8h7wS8El-ZTqUUtFONVjUdLwdQrshKNrJgwlX5NVpxzzXhb8WNyUsoDpi03-g05lsYo1Sq5Ij_vlzEtmY7B5wTxMeQUR4gz9YPLzs-QQ3FzSJHOiZY5473f0wkDQoX2KdNhP0GeB8ioQUNEBvMwpwhuhzIwpqeim_ZYpEPYDmyb3QZogZyWQtOjy8FF6l30kOnZ3ffrm6-XaybO35Kj3u0KvHuOp-Tbl8v79TW7vbu6WX--ZV5WamZNZ_q2UVqLTom23njDRV81uvf4ya4F33Dnlap632snDK9kp0zT1KC5qjsh5Sk5O-hOOf1YoMx2DMXDbuci4IRWcqVb3GsjEP34D_qA24s4HVLGtEYLYZCqDhTutJQMvZ1yGF3eW8Htk3X2YJ1F6-xv66zCpg_P0ks3wuZPy4tXCMgDULAUt5D_vv0f2V9ccaae</recordid><startdate>20240824</startdate><enddate>20240824</enddate><creator>Aronson, S. Lot</creator><creator>Walker, Cédric</creator><creator>Thijssen, Bram</creator><creator>van de Vijver, Koen K.</creator><creator>Horlings, Hugo M.</creator><creator>Sanders, Joyce</creator><creator>Alkemade, Maartje</creator><creator>Koole, Simone N.</creator><creator>Lopez-Yurda, Marta</creator><creator>Lok, Christianne A. R.</creator><creator>Rottenberg, Sven</creator><creator>van Rheenen, Jacco</creator><creator>Sonke, Gabe S.</creator><creator>van Driel, Willemien J.</creator><creator>Kester, Lennart A.</creator><creator>Hahn, Kerstin</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8175-1647</orcidid><orcidid>https://orcid.org/0000-0003-2246-1994</orcidid><orcidid>https://orcid.org/0000-0001-7262-1015</orcidid><orcidid>https://orcid.org/0000-0003-4782-8828</orcidid><orcidid>https://orcid.org/0000-0003-3602-4234</orcidid><orcidid>https://orcid.org/0000-0002-2026-9790</orcidid><orcidid>https://orcid.org/0000-0003-3678-3222</orcidid><orcidid>https://orcid.org/0000-0003-1562-2649</orcidid><orcidid>https://orcid.org/0000-0002-0551-7813</orcidid></search><sort><creationdate>20240824</creationdate><title>Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)</title><author>Aronson, S. Lot ; Walker, Cédric ; Thijssen, Bram ; van de Vijver, Koen K. ; Horlings, Hugo M. ; Sanders, Joyce ; Alkemade, Maartje ; Koole, Simone N. ; Lopez-Yurda, Marta ; Lok, Christianne A. R. ; Rottenberg, Sven ; van Rheenen, Jacco ; Sonke, Gabe S. ; van Driel, Willemien J. ; Kester, Lennart A. ; Hahn, Kerstin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-5b8f956771b6194dc801f257fc866b9ec50ac662fcf7a18023b68554e7064b133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/67/1517/1709</topic><topic>631/67/1857</topic><topic>692/4028/67/1517/1709</topic><topic>692/53/2423</topic><topic>Aged</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - immunology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Cystadenocarcinoma, Serous - drug therapy</topic><topic>Cystadenocarcinoma, Serous - pathology</topic><topic>Cystadenocarcinoma, Serous - therapy</topic><topic>Cytoreduction Surgical Procedures</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Hyperthermic Intraperitoneal Chemotherapy</topic><topic>Lymphocytes B</topic><topic>Macrophages</topic><topic>Macrophages - pathology</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Patients</topic><topic>Transcriptomes</topic><topic>Tumor Microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aronson, S. Lot</creatorcontrib><creatorcontrib>Walker, Cédric</creatorcontrib><creatorcontrib>Thijssen, Bram</creatorcontrib><creatorcontrib>van de Vijver, Koen K.</creatorcontrib><creatorcontrib>Horlings, Hugo M.</creatorcontrib><creatorcontrib>Sanders, Joyce</creatorcontrib><creatorcontrib>Alkemade, Maartje</creatorcontrib><creatorcontrib>Koole, Simone N.</creatorcontrib><creatorcontrib>Lopez-Yurda, Marta</creatorcontrib><creatorcontrib>Lok, Christianne A. R.</creatorcontrib><creatorcontrib>Rottenberg, Sven</creatorcontrib><creatorcontrib>van Rheenen, Jacco</creatorcontrib><creatorcontrib>Sonke, Gabe S.</creatorcontrib><creatorcontrib>van Driel, Willemien J.</creatorcontrib><creatorcontrib>Kester, Lennart A.</creatorcontrib><creatorcontrib>Hahn, Kerstin</creatorcontrib><creatorcontrib>OVHIPEC-1 Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aronson, S. Lot</au><au>Walker, Cédric</au><au>Thijssen, Bram</au><au>van de Vijver, Koen K.</au><au>Horlings, Hugo M.</au><au>Sanders, Joyce</au><au>Alkemade, Maartje</au><au>Koole, Simone N.</au><au>Lopez-Yurda, Marta</au><au>Lok, Christianne A. R.</au><au>Rottenberg, Sven</au><au>van Rheenen, Jacco</au><au>Sonke, Gabe S.</au><au>van Driel, Willemien J.</au><au>Kester, Lennart A.</au><au>Hahn, Kerstin</au><aucorp>OVHIPEC-1 Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2024-08-24</date><risdate>2024</risdate><volume>131</volume><issue>3</issue><spage>565</spage><epage>576</epage><pages>565-576</pages><issn>0007-0920</issn><issn>1532-1827</issn><eissn>1532-1827</eissn><abstract>Background
Hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in patients with Stage III ovarian cancer following interval cytoreductive surgery (CRS). Optimising patient selection is essential to maximise treatment efficacy and avoid overtreatment. This study aimed to identify biomarkers that predict HIPEC benefit by analysing gene signatures and cellular composition of tumours from participants in the OVHIPEC-1 trial.
Methods
Whole-transcriptome RNA sequencing data were retrieved from high-grade serous ovarian cancer (HGSOC) samples from 147 patients obtained during interval CRS. We performed differential gene expression analysis and applied deconvolution methods to estimate cell-type proportions in bulk mRNA data, validated by histological assessment. We tested the interaction between treatment and potential predictors on progression-free survival using Cox proportional hazards models.
Results
While differential gene expression analysis did not yield any predictive biomarkers, the cellular composition, as characterised by deconvolution, indicated that the absence of macrophages and the presence of B cells in the tumour microenvironment are potential predictors of HIPEC benefit. The histological assessment confirmed the predictive value of macrophage absence.
Conclusion
Immune cell composition, in particular macrophages absence, may predict response to HIPEC in HGSOC and these hypothesis-generating findings warrant further investigation.
Clinical trial registration
NCT00426257.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38866963</pmid><doi>10.1038/s41416-024-02731-6</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8175-1647</orcidid><orcidid>https://orcid.org/0000-0003-2246-1994</orcidid><orcidid>https://orcid.org/0000-0001-7262-1015</orcidid><orcidid>https://orcid.org/0000-0003-4782-8828</orcidid><orcidid>https://orcid.org/0000-0003-3602-4234</orcidid><orcidid>https://orcid.org/0000-0002-2026-9790</orcidid><orcidid>https://orcid.org/0000-0003-3678-3222</orcidid><orcidid>https://orcid.org/0000-0003-1562-2649</orcidid><orcidid>https://orcid.org/0000-0002-0551-7813</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2024-08, Vol.131 (3), p.565-576 |
| issn | 0007-0920 1532-1827 1532-1827 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3067915351 |
| source | MEDLINE; SpringerLink Journals |
| subjects | 631/67/1517/1709 631/67/1857 692/4028/67/1517/1709 692/53/2423 Aged Biomarkers Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Biomarkers, Tumor - immunology Biomedical and Life Sciences Biomedicine Cancer Research Chemotherapy Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - pathology Cystadenocarcinoma, Serous - therapy Cytoreduction Surgical Procedures Drug Resistance Epidemiology Female Gene expression Humans Hyperthermic Intraperitoneal Chemotherapy Lymphocytes B Macrophages Macrophages - pathology Middle Aged Molecular Medicine Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Patients Transcriptomes Tumor Microenvironment Tumors |
| title | Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T08%3A13%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumour%20microenvironment%20characterisation%20to%20stratify%20patients%20for%20hyperthermic%20intraperitoneal%20chemotherapy%20in%20high-grade%20serous%20ovarian%20cancer%20(OVHIPEC-1)&rft.jtitle=British%20journal%20of%20cancer&rft.au=Aronson,%20S.%20Lot&rft.aucorp=OVHIPEC-1%20Study%20Group&rft.date=2024-08-24&rft.volume=131&rft.issue=3&rft.spage=565&rft.epage=576&rft.pages=565-576&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-024-02731-6&rft_dat=%3Cproquest_cross%3E3088987118%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3088987118&rft_id=info:pmid/38866963&rfr_iscdi=true |